NCT06895473View on ClinicalTrials.gov

Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

December 31, 2027

Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
PROCEDURE

Biospecimen Collection

Undergo CSF sample collection

DRUG

Cytarabine

Given IT

PROCEDURE

Lumbar Puncture

Undergo lumbar puncture

DRUG

Methotrexate

Given IT

DRUG

Therapeutic Hydrocortisone

Given IT

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

collaborator

American Society of Clinical Oncology

OTHER

lead

OHSU Knight Cancer Institute

OTHER